Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 1.00 |
| ▸ | JAK2 | O60674 | 13/20 | 1.00 |
| ▸ | JAK1 | P23458 | 10/20 | 1.00 |
| ▸ | TYK2 | P29597 | 5/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.62 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.58 |
| ▸ | MARK3 | P27448 | 2/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.58 |
| ▸ | STK3 | Q13188 | 2/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.58 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.58 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.58 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.58 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.58 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28403909 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL1120769 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL28403918 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL16809397 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL28403926 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Hydrogen Sulfide SCHEMBL28763305 | 0.99 | JAK3 (0.98) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL27676940 | 0.91 | JAK3 (0.84) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4064027 | 0.91 | JAK3 (0.83) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4072656 | 0.90 | JAK3 (0.82) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4060476 | 0.90 | JAK3 (0.82) | JAK3JAK2JAK1TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828380-B2 | Efficient method for the preparation of tofacitinib citrate | OLON S.P.A. (IT) | 2017-11-28 | — | — | US | claimed |
| US-20160297825-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | OLON S.P.A. (IT) | 2016-10-13 | — | — | US | claimed |
| EP-3078665-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | OLON S.p.A. (IT) | 2016-10-12 | — | — | EP | claimed |
| CN-105440039-A | Synthesis method of tofacitinib citrate | SHANDONG ZIBO XINCAT PHARMACEUTICAL CO LTD | 2016-03-30 | — | — | CN | claimed |
| WO-2021084556-A1 | Process for the preparation of tofacitinib and intermediates thereof | AARTI INDUSTRIES LIMITED (IN) | 2021-05-06 | — | — | WO | disclosed |
| WO-2020183295-A1 | PROCESS FOR PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | INTAS PHARMACEUTICALS LTD. (IN) | 2020-09-17 | — | — | WO | disclosed |
| WO-2018172821-A1 | NOVEL TOFACITINIB ADDITION SALTS AND PROCESS FOR THE PREPARATION THEREOF | PHALANX LABS PRIVATE LIMITED (IN) | 2018-09-27 | — | — | WO | disclosed |
| US-9856261-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856261-B2 | Piperidine inhibitors of Janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9828380-B2 | Efficient method for the preparation of tofacitinib citrate | OLON S.P.A. (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828380-B2 | Efficient method for the preparation of tofacitinib citrate | OLON S.P.A. (IT) | 2017-11-28 | — | — | US | disclosed |
| EP-3026052-A9 | PREPARATION OF DEUTERATED PIPERIDINE INHIBITORS OF JANUS KINASE 3 | Auspex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20030073719-A1 | Chiral salt resolution | PFIZER INC. | 2003-04-17 | — | — | US | disclosed |
| CN-1409712-A | Pyrrolo [2, 3-d ] pyrimidine compounds | PFIZER PROD INC (US) | 2003-04-09 | — | — | CN | disclosed |
| EP-1294724-A1 | PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | Pfizer Products Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1235830-A2 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002000661-A1 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| US-20010053782-A1 | Immunosuppressants; organ transplant | BLUMENKOPF TODD A (US) | 2001-12-20 | — | — | US | disclosed |
| WO-2001042246-A2 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | JAK3 3/4885JAK2 6/4885JAK1 1/4885 |
| US-20160297825-A1 | EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE | IDH1, AURKC, COASY | JAK3 14/4885JAK2 11/4885JAK1 18/4885 |
| US-20030073719-A1 | Chiral salt resolution | REN, SRR, RER1 | JAK3 4250/4885JAK2 3069/4885JAK1 3549/4885 |
| US-20010053782-A1 | Immunosuppressants; organ transplant | JAK1, JAK3, TPMT | JAK3 2/4885JAK2 14/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.